207_Combined course Presentations

DAHANCA 10 randomized phase III

LARYNX, PHARYNX* and ORAL CAVITY T1-4,N0-3, M0 (not st 1 glottic larynx)

* Except NPC

Low hemoglobin value: < 9.0 mmol/l (14.5 g/dl).

Acclerated RT (6 fx/week) (66-68 Gy/33-34 fx) + Hypoxic sensitizer: Nimorazol

Stratify by:

Gender Site

T&N stage WHO perf. Institution

Aranesp® (darbepoetin alpha ) Weekly subcutaneously injection

Acclerated RT (6 fx/week) (66-68 Gy/33-34 fx) + Hypoxic sensitizer: Nimorazol

RANDOMIZE

+

Overgaard et al ICHNO 2013